evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4 questions · 4 findings · 1 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%

TMP/SMX vs placebo, no treatment or non‐PCP drug

All‐cause mortality ‐ sensitivity analysis · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients

TMP/SMX showed no clear difference in all cause mortality ‐ TMP/SMX versus placebo or no treatment compared with placebo, no treatment or non‐PCP drug (low certainty).

1 finding from 1 review

TMP/SMX vs placebo, no treatment or non‐PCP drug

Adverse events: severe adverse events requiring treatment discontinuation ‐ TMP/SMX versus placebo or no treatment Clinical and laboratory criteria and treatment discontinuations · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients

TMP/SMX showed no clear difference in adverse events: severe adverse events requiring treatment… compared with placebo, no treatment or non‐PCP drug (moderate certainty).

1 finding from 1 review

TMP/SMX vs placebo, no treatment or non‐PCP drug

PCP‐related mortality Clinical only · patients with Pneumocystis pneumonia (PCP) in non‐HIV immunocompromised patients

TMP/SMX may leads to lower PCP‐related mortality Clinical only compared with placebo, no treatment or non‐PCP drug (low certainty).

1 finding from 1 review